Clinical Research Directory
Browse clinical research sites, groups, and studies.
The Impact of Nicotinamide Mononucleotide Sustained-release Tablets on Immunosenescence and Metabolism in Middle-aged and Elderly Individuals With Metabolic Disorders.
Sponsor: Qing Su
Summary
This study evaluates whether nicotinamide mononucleotide (NMN) sustained-release tablets affect markers of immune system aging in adults aged 50 to 70 years with overweight or obesity and metabolic disorders. It compares NMN, 1,000 mg once daily for 26 weeks, with a matching placebo. The main assessment is the change from baseline in the proportion of a blood T-cell population associated with immune system aging. The study also evaluates liver fat, blood sugar regulation, body composition, other immune and metabolic markers, and cardiorespiratory fitness, together with laboratory measures of safety.
Key Details
Gender
All
Age Range
50 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
124
Start Date
2025-06-05
Completion Date
2026-10-18
Last Updated
2026-11-03
Healthy Volunteers
No
Conditions
Interventions
NMN
Nicotinamide mononucleotide (NMN) sustained-release tablets, 1,000 mg per tablet, administered orally as one tablet once daily before breakfast for 26 weeks.
Placebo
Matching placebo tablets, administered orally as one tablet once daily before breakfast for 26 weeks.
Locations (1)
Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, China